Member Info for Soupdragon78

Half decent amount of buying today and typically WINS pull it down.

Jay, whilst its fair to say NXP002 is the only game in town to a certain extent. I would like the think they could score an easy win with NXP001, surely there must be some sort of interest in the product even for a modest price. At least it would get some momentum behind the company whilst they deal with the bigger product.

Once again, RedX showing whats possible, signing a deal for $20m in upfront and up to $400m in development and milestones.

Mikey, what would you want a new CEO with 2 employees to do to drive the company forward?

CEO - Muhunthan Thillai
Strategic advisor - Dan Gooding

The Qur8 team are looking increasingly familiar.

Is this the same goup who on 2nd of Aug said

“Well this is it approximately 4 weeks to announce a deal , if they don't achieve it in august they never will...”

Yuyu’s, fair enough but the twitter ramp started on Wednesday afternoon with buying at 3.7p

I do think the crowd on there can influence the sp, ************ bought circa 550k which helped the turn around, he then has over a thousand followers who jump onboard. Problem is they get caught by the spread.

Disappointing but unsurprising performance today. Was obvious yesterday, as I mentioned it was a pump with 4p target. Pity some got suckered by it with a number of paired sells at a loss today.

When I say presenting later, they’re doing it in 20mins, @ 4pm.

Anyway, I’m sure our top researcher were going to post today’s Vistagen news from their second pre clinical study of AV-101

"These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS indications," said Shawn Singh, Chief Executive Officer of VistaGen. "The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination."

They are also presenting later today.

VistaGen's Chief Executive Officer, Shawn Singh, is scheduled to present on Thursday, September 3, 2020, at 11 a.m. EDT / 8 a.m. PDT. This presentation will be webcast live, and all investors are welcome to watch by registering at https://www.webcaster4.com/Webcast/Page/2019/36581

VistaGen's conference profile can be viewed at http://www.ldmicro.com/profile/VTGN

I see Karl Keegan is on his bike again, at least it’s just RoSpa this time, although seems to be saying he’s ‘looking for a move.’

Hale, is tranilast FDA approved?

Should read Ofev not Ofer

Interesting Halespur, also interesting is that Ofer outsells Esbriet.

“Our focus is now on the development of a formulation and delivery process that exploits the optimal means to treat fibrosis of the lungs, through nebulisation of the drug to facilitate inhalation by the patient. We are considering a number of inhalation devices that would enable rapid and deep penetration of the drug into the lungs with a view to evaluating them further.”

Would be good to hear that formulation and delivery has be nailed down. That opens the gateway to clinical trials.

Poor Kev, it seems Alex has left him out to hang, not telling him when he sells. Agenda's you know.

And yet you never want to tell anyone how many you hold. Its as if you buy and sell on the spikes as well.

That’s odd scary, you keep trying to tell people I’ve sold.

Shall we start up the deal by end of August postings again? At least they allowed those who posted them to sell up and buy back lower.